Publications by authors named "J Lockman"
Eval Program Plann
April 2025
Article Synopsis
- The study emphasizes the importance of measuring therapist fidelity in cognitive behavioral therapy for insomnia (CBT-I), focusing on both adherence to treatment and the competence of delivery.
- Researchers developed reliable measures of therapist fidelity specifically for brief CBT-I and conducted a pilot study with veterans to evaluate their impact.
- Results indicated that higher therapist adherence was significantly linked to reduced depression, highlighting the influence of fidelity on treatment outcomes.
Circ Heart Fail
January 2025
Article Synopsis
- - Mavacamten is a cardiac myosin inhibitor approved by the FDA specifically for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), requiring monitoring for heart failure and low left ventricular ejection fraction (LVEF) as part of a risk management program.
- - Data from the mavacamten REMS database, spanning from April 2022 to February 2024, included over 6,000 patients, revealing that 4.6% experienced a decrease in LVEF to below 50%, while 1.3% required hospitalization for heart failure.
- - A majority of patients remained on the prescribed doses of mavacamten, with significant improvements in heart function observed: 57.
